FDA — authorised 26 July 1999
- Marketing authorisation holder: GLAXOSMITHKLINE
- Status: approved
🇺🇸 Relenza in United States
FDA authorised Relenza on 26 July 1999
Marketing authorisations
FDA — authorised 26 July 1999
- Application: NDA021036
- Marketing authorisation holder: GLAXOSMITHKLINE
- Local brand name: RELENZA
- Indication: POWDER — INHALATION
- Status: approved
Relenza in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United States
Frequently asked questions
Is Relenza approved in United States?
Yes. FDA authorised it on 26 July 1999; FDA authorised it on 26 July 1999.
Who is the marketing authorisation holder for Relenza in United States?
GLAXOSMITHKLINE holds the US marketing authorisation.